For adult patients uncontrolled on one or more antidiabetic oral agents in addition to diet and exercise.
In a 24 week clinical trial versus Exenatide it decreased Hemoglobin A1C hemoglobin by 1.6%.
Slows gastric emptying time and can reduce the rate of absorption of orally administered drugs.
Can increase INR in patients on warfarin therapy.